BACKGROUND: Guidelines recommend reducing treatment in patients with well-controlled asthma after 3 months of stability. However, there is inadequate real-life data to guide physicians on therapy change in daily practice.
OBJECTIVE: To assess asthma control after change to and step-down of fluticasone propionate/formoterol fumarate dihydrate (FP/FOR) in real-life patients.
METHODS: In a randomized controlled, pragmatic, open-label trial, 225 well-controlled patients with asthma were randomized (1:2) to maintain high-dose fluticasone propionate/salmeterol xinafoate (FP/SAL, 1000/100 μg) or switch to FP/FOR (1000/40 μg) daily for 12 weeks (phase 1). One hundred sixteen patients stable on FP/FOR at week 12 were subsequently randomized (1:1) to maintain this therapy, or stepped down to FP/FOR (500/20 μg) daily for 12 weeks (phase 2). The primary end point was the 7-question Asthma Control Questionnaire (ACQ7) score.
RESULTS: In phase 1, FP/FOR (1000/40 μg) (n = 126) was noninferior to FP/SAL (1000/100 μg) (n = 73) for ACQ7 (difference in means, -0.12; 95% CI, -0.32 to 0.09). In phase 2, FP/FOR (500/20 μg) (n = 52) was noninferior to FP/FOR (1000/40 μg) (n = 52) for ACQ7 (difference in means, 0.01; 95% CI, -0.20 to 0.22). There was no significant difference in exacerbation rate between the groups in either phase. However, 1 to 2 exacerbations in 12 months before phase 1 were associated with the occurrence of an exacerbation after step-down (P = .007).
CONCLUSIONS: In patients with well-controlled asthma, a change from FP/SAL to FP/FOR did not compromise asthma control. Step-down of FP/FOR was well tolerated; however, in contrast to current guidelines, our data suggest caution in stepping down patients uncontrolled in the last 12 months. Larger step-down studies are required to confirm these findings.
|Number of pages||10|
|Journal||The journal of allergy and clinical immunology. In practice|
|Early online date||25 Mar 2017|
|Publication status||Published - Sept 2017|
We thank the study participants and the principal investigators and staff at the study sites for their contributions (listed in Table E7 in this article's Online Repository at www.jaci-inpractice.org). We are grateful to Optimum Patient Care Ltd research nurses Latife Hardaker, Miriam Cottle, Susanne Skinner, and Amanda Rosenberg and to Interface Clinical Services for site and patient recruitment and conduct of study clinics. We thank the Research in Real Life Ltd study team members Marjan Bojarnejad, Elwira Fidziukiewicz, Clare Fraser, Tahreem Sarwar, Cate Savage, and Natalie Tett for their support in the setup and conduct of the study and Clinical Studies lead Sandra Kreuzaler for study oversight. We also thank Alessandra Cifra for support with medical writing. MedDRA is owned by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) on behalf of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
- Combination therapy
- Fractional exhaled nitric oxide
- Inhaled corticosteroids
- Pragmatic trials
- Antiasthmatic agents